Adjuvant chemotherapy for high-risk endometrial cancer
- 31 January 2000
- journal article
- review article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 10 (1) , 23-28
- https://doi.org/10.1016/s1053-4296(00)80017-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Postoperative Adjuvant Cisplatin, Doxorubicin, and Cyclophosphamide (PAC) Chemotherapy in Women with High-Risk Endometrial CarcinomaGynecologic Oncology, 1994
- Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinomaAmerican Journal of Obstetrics and Gynecology, 1994
- Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)Gynecologic Oncology, 1992
- Uterine Papillary Serous CarcinomaObstetrical & Gynecological Survey, 1991
- Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group studyGynecologic Oncology, 1991
- Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: A preliminary analysisGynecologic Oncology, 1990
- Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group studyGynecologic Oncology, 1990
- A randomized trial of adjuvant progestagen in early endometrial cancerCancer, 1989
- Postoperative external pelvic irradiation in carcinoma of the corpus stage I: A controlled clinical trialGynecologic Oncology, 1976
- Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancerGynecologic Oncology, 1974